Cubist Systematic Strategies, LLC Assembly Biosciences, Inc. Transaction History

Cubist Systematic Strategies, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.7 - $20.52 $15,476 - $186,814	-9,104 Reduced 31.44%	19,857 $33,000
Q3 2022 Nov 14, 2022	SELL	$1.7 - $20.52 $15,476 - $186,814	-9,104 Reduced 31.44%	19,857 $33,000
Q2 2022 Aug 15, 2022	BUY	$1.35 - $2.29 $39,097 - $66,320	28,961 New	28,961 $61,000
Q1 2022 May 16, 2022	SELL	$1.46 - $2.45 $52,054 - $87,352	-35,654 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.13 - $3.46 $35,784 - $58,128	16,800 Added 89.11%	35,654 $83,000
Q3 2021 Nov 15, 2021	SELL	$3.14 - $3.9 $45,288 - $56,249	-14,423 Reduced 43.34%	18,854 $66,000
Q2 2021 Aug 16, 2021	SELL	$3.8 - $4.56 $105,062 - $126,074	-27,648 Reduced 45.38%	33,277 $129,000
Q1 2021 May 17, 2021	SELL	$4.33 - $6.63 $282,173 - $432,057	-65,167 Reduced 51.68%	60,925 $280,000
Q4 2020 Feb 16, 2021	BUY	$4.87 - $17.29 $614,068 - $2.18 Million	126,092 New	126,092 $763,000
Q4 2019 Feb 14, 2020	SELL	$8.36 - $23.81 $199,319 - $567,678	-23,842 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$9.83 - $14.82 $25,921 - $39,080	-2,637 Reduced 9.96%	23,842 $234,000
Q2 2019 Aug 14, 2019	SELL	$12.9 - $20.8 $4,669 - $7,529	-362 Reduced 1.35%	26,479 $357,000
Q1 2019 May 15, 2019	BUY	$17.7 - $24.93 $157,919 - $222,425	8,922 Added 49.79%	26,841 $528,000
Q4 2018 Feb 14, 2019	BUY	$19.05 - $36.45 $341,356 - $653,147	17,919 New	17,919 $405,000
Q2 2018 Aug 14, 2018	SELL	$39.21 - $50.29 $351,478 - $450,799	-8,964 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$41.7 - $64.16 $373,798 - $575,130	8,964 New	8,964 $440,000

16.3K

Ticker ASMB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,436,900
Market Cap $733M
Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.